Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Up 205.1% in August

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a large growth in short interest in August. As of August 14th, there was short interest totaling 51,809 shares, a growth of 205.1% from the July 30th total of 16,980 shares. Approximately 1.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 11,844,452 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BJDX. Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Wednesday, June 24th. Wall Street Zen cut Bluejay Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bluejay Diagnostics presently has an average rating of “Sell”.

Insider Buying and Selling

In other news, major shareholder Financial Lp Hrt bought 64,047 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The shares were acquired at an average price of $1.51 per share, with a total value of $96,710.97. Following the acquisition, the insider owned 126,993 shares of the company’s stock, valued at approximately $191,759.43. The trade was a 101.75% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC bought a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. Institutional investors and hedge funds own 18.47% of the company’s stock.

Bluejay Diagnostics Stock Down 1.0%

Shares of Bluejay Diagnostics stock traded down $0.01 during trading on Friday, reaching $0.90. The company’s stock had a trading volume of 11,268,520 shares, compared to its average volume of 6,139,525. Bluejay Diagnostics has a 52-week low of $0.83 and a 52-week high of $16.68. The company has a market cap of $4.02 million, a price-to-earnings ratio of -0.13 and a beta of 0.89. The firm’s 50-day moving average is $1.34 and its two-hundred day moving average is $2.04.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its earnings results on Wednesday, August 12th. The company reported ($1.12) EPS for the quarter, topping analysts’ consensus estimates of ($3,520.00) by $3,518.88.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.